Last Update 09 May 26

Fair value Decreased 6.18%

HCAT: New Leadership And AI Investments Will Drive Post Review Turnaround

Narrative Update on Health Catalyst

The updated analyst price target for Health Catalyst has shifted lower toward a cluster around $2, reflecting analyst caution after reduced targets and commentary around softer near term guidance, the ongoing transition from DOS to Ignite, and the company’s current strategic and operational reviews.

Analyst Commentary

Recent research reflects a cautious stance on Health Catalyst, with price targets clustered in the US$1.75 to US$3.00 range and several firms highlighting execution risk around guidance, product transition, and ongoing reviews.

Bullish Takeaways

Bullish analysts see potential in new leadership and AI-focused investments as longer term drivers that could support growth and valuation if execution improves over time.
Some analysts maintain positive ratings even with lower targets, suggesting they still view the stock as mispriced relative to the company’s longer term opportunities once current uncertainties clear.
The view that applications layer demand remains intact signals that, if Health Catalyst can align its offerings with client needs, revenue growth could benefit over time.
Analysts who stay constructive describe the current period as one where investors may prefer to wait for the outcome of strategic and operational reviews rather than abandoning the thesis entirely.

Bearish Takeaways

Bearish analysts highlight that Q1 revenue and EBITDA guidance is below prior consensus and that FY26 guidance has been deferred, which adds uncertainty to medium term growth and earnings visibility.
The transition from DOS to Ignite is expected to involve down-selling and possible customer attrition in some cases, which could weigh on near term revenue and margin execution.
Multiple price target cuts into the low single digits signal reduced confidence in the company’s ability to deliver on prior expectations, with some analysts indicating there is “nothing to do right now” until reviews conclude.
Some analysts remain on the sidelines and want more conclusive evidence that the company can execute its strategy before becoming more constructive, which can limit multiple expansion in the near term.

What's in the News

Ben Albert, previously President and COO, has been appointed CEO and joined the Board of Directors. Former CEO Dan Burton has stepped down from the Board and is expected to remain as a strategic advisor (Executive Changes).
The company reported goodwill and intangible asset impairment charges of $81,454,000 for the fourth quarter ended December 31, 2025, linked to the Technology and Professional Services reporting units (Impairments/Write Offs).
Health Catalyst announced Project Nexus, which includes a workforce reduction of about 9% and the elimination of around 100 additional open positions across the US and India. The initiative is aimed at aligning resources with key technology opportunities and reducing the cost structure (Discontinued Operations/Downsizings).
The company provided earnings guidance for the first quarter of 2026, expecting total revenue of US$68m to US$70m (Corporate Guidance).
Health Catalyst reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares under its existing buyback, and that it has completed total repurchases of 1,957,767 shares, or 3.3%, for US$15.16m under the program announced on August 4, 2022 (Buyback Tranche Update).

Valuation Changes

Fair Value: Updated estimate has fallen slightly from $2.09 to $1.96.
Discount Rate: Lowered from 12.33% to about 11.49%, indicating a modest reduction in the assumed risk level used in the model.
Revenue Growth: Forecast has weakened from a 0.96% decline to a 1.87% decline, pointing to a more cautious view on $ revenue trends.
Net Profit Margin: Assumption has been trimmed from 6.37% to about 5.62%, reflecting lower expected profitability.
Future P/E: Target multiple has risen slightly from 13.26x to about 14.18x, indicating a small uplift in the valuation multiple applied to future earnings.

0 views

Key Takeaways

Expansion of AI-driven solutions and proprietary data assets, along with industry trends, will drive margin growth, premium pricing, and sustained revenue gains.
Platform migration and cost restructuring set the stage for improved profitability, operating leverage, and consistent technology segment growth.
Health Catalyst faces ongoing revenue pressure from client spending cuts, strategic downsizing, and macroeconomic headwinds, with uncertain prospects for sustained growth and profitability.

Catalysts

About Health Catalyst

Provides data and analytics technology and services to healthcare organizations in the United States.What are the underlying business or industry changes driving this perspective?

The company's focus on expanding its high-margin applications portfolio, driven by ongoing client cross-sell momentum and strong adoption of modular AI-enabled solutions, is positioned to accelerate gross margin expansion and adjusted EBITDA growth as macro headwinds stabilize (positively impacting margins and earnings).
Migration of platform clients to the new Ignite infrastructure is expected to largely complete by mid-2026, at which point the current revenue headwinds from clients "pocketing" migration cost savings will subside-setting the stage for renewed and more consistent Technology segment growth (positively impacting revenue trajectory).
Secular industry drivers-including the shift to value-based care and the demand for advanced data analytics to meet regulatory and efficiency goals-are expected to support ongoing demand for Health Catalyst's core offerings, expanding its addressable market and sustaining longer-term revenue growth.
Management's proactive cost restructuring, contract repricing, and organizational streamlining are on track to deliver $40 million in annualized profitability improvements, enabling sustainable operating leverage and improvements in net margin and free cash flow-well ahead of earlier targets.
The company's substantial investment in proprietary data assets, AI/ML-driven analytics, and its ability to leverage deep integration with over 1,100 healthcare clients position it to command premium pricing, foster high retention, and benefit disproportionately as digitization and AI adoption accelerate across the healthcare sector (driving both revenue and margin expansion).

Health Catalyst Earnings and Revenue Growth

Health Catalyst Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Health Catalyst's revenue will decrease by 1.9% annually over the next 3 years.
Analysts are not forecasting that Health Catalyst will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Health Catalyst's profit margin will increase from -57.2% to the average US Healthcare Services industry of 5.6% in 3 years.
If Health Catalyst's profit margin were to converge on the industry average, you could expect earnings to reach $16.5 million (and earnings per share of $0.19) by about May 2029, up from -$178.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 14.3x on those 2029 earnings, up from -0.7x today. This future PE is lower than the current PE for the US Healthcare Services industry at 30.2x.
Analysts expect the number of shares outstanding to grow by 5.73% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 11.49%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant and accelerated Medicaid and research funding cuts are causing widespread financial strain and uncertainty among Health Catalyst's core end markets-especially not-for-profit and academic medical center clients-which is leading to lower client spending, smaller extension contracts, and delayed bookings, directly impacting both near
and long-term revenue growth.
A pronounced trend of existing clients "pocketing" cost savings from Ignite platform migrations, rather than reinvesting these savings in expansion or new offerings, is compressing dollar-based net retention to the low 90s and creating persistent top-line headwinds that are expected to last at least through mid-2026.
The company's Professional Services segment faces strategic downsizing, including the exit of lower-margin or unprofitable contracts and workforce reductions impacting 9% of employees, resulting in immediate declines in Services revenue in 2025 and 2026, and introducing risk of weakened client support and scalability, negatively affecting both revenue and operating consistency.
Persistent macroeconomic pressures, such as inflation and potential expiration of premium subsidies, combined with industry conservatism and risk aversion, are causing health systems to defer or shrink technology spending, limiting the pace of Health Catalyst's pipeline conversion and new client acquisition and thus dampening revenue growth prospects for 2026 and possibly 2027.
The company's removal of ambitious 2028 revenue and EBITDA targets, stated cessation of near
to mid-term M&A activity, and reliance on maintaining profitability through restructuring rather than organic top-line growth, collectively raise concerns about Health Catalyst's ability to reignite sustainable revenue expansion-a risk that could constrain future earnings momentum and share price appreciation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $1.96 for Health Catalyst based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.0, and the most bearish reporting a price target of just $1.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $294.0 million, earnings will come to $16.5 million, and it would be trading on a PE ratio of 14.3x, assuming you use a discount rate of 11.5%.
Given the current share price of $1.59, the analyst price target of $1.96 is 19.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Health Catalyst?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Modular AI Solutions Will Transform Value-Based Healthcare